The objective of this article is to review the literature related to the pathophysiology of fibromyalgia and the drug therapy used to treat this disease. Fibromyalgia, the second most frequently diagnosed rheumatological disorder, has complex interrelated pathologies that must be addressed to achieve effective symptom control. Central and peripheral sensitization along with neurotransmitter abnormalities play a major role in defining the symptoms associated with this disease. Drug therapy must be multifaceted because no single drug addresses all pathologies. Drug and nondrug therapies showing strong-to-moderate effectiveness should be used to obtain the most benefit.
Wolfe F., Ross K., Anderson J., Russell IJ, Hebert L.The prevalence and characteristics of fibromyalgia in the general population . Arthritis Rheum. 1995;38:19-28.
Chakrabarty S., Zoorob R.Fibromyalgia. Am Fam Physician . 2007;76:247-254.
7.
Wolfe F., Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum.1990;33:160-172.
8.
Landis CA, Lentz MJ, Tsuji J., Buchwald D., Shaver JLPain, psychological variables, sleep quality, and natural killer cell activity in midlife women with and without fibromyalgia. Brain Behav Immun. 2004;18:304-313.
9.
Clayton AH, West SGCombination therapy in fibromyalgia. Curr Pharm Des. 2006;12:11-16.
10.
Wolfe F.The clinical syndrome of fibrositis. Am J Med. 1986;81(suppl 3A):7-14.
11.
Yunus MB, Masi AT, Aldag JCA controlled study of primary fibromyalgia syndrome: clinical features and associations with other functional syndromes. J Rheumatol . 1989;16(suppl 19):62-71.
12.
Marcus DA, Bernstein C., Rudy TEFibromyalgia and headache: an epidemiological study supporting migraine as part of the fibromyalgia syndrome. Clin Rheumatol. 2005;24:595-601.
13.
Nicolodi M. , Sicuteri F.Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy . Adv Exp Med Biol.1996;398:373-379.
14.
Sperber AD, Atzmon Y., Neumann L., et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol. 1999;94: 3541-3546.
15.
Harding SMSleep in fibromyalgia patients: subjective and objective findings . Am J Med Sci. 1998;315:367-376.
16.
Staud R.Treatment of fibromyalgia and its symptoms. Expert Opin Pharmachother . 2007;8:1629-1642.
17.
Kasikcioglu E., Dinler M., Berker E.Reduced tolerance of exercise in fibromyalgia may be a consequence of impaired mirocirculation initiated by deficient action of nitric oxide. Med Hypotheses . 2006;66:950-952.
18.
Wallace DJIs there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des. 2006;12:17-22.
19.
Bazzichi L. , Rossi A., Massimetti G., et al. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol. 2007;25:225-230.
20.
Vierck CJ Jr.Mechanisms underlying development of spatially distributed chronic pain (fibromyalgia). Pain. 2006;124:242-263.
21.
Littlejohn GO, Guymer EKFibromyalgia syndrome: which antidepressant drugs should we choose. Curr Pharm Des. 2006 ;12:3-9.
22.
Russell IJAdvances in fibromyalgia: possible role for central neurochemicals . Am J Med Sci. 1998;315: 377-384.
23.
Suzuki R., Hunt SP, Dickenson AHThe coding of noxious mechanical and thermal stimuli of deep dorsal horn neurons is attenuated in NK1 knockout mice. Neuropharmacology . 2003;45:1093-1100.
24.
Neeck G., Crofford IJNeuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome . Rheum Dis Clin North Am. 2000;26:989-1002.
25.
Crofford LJ , Young EA, Engleberg NC, et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun. 2004;18:314-325.
26.
Bazzichi L. , Giannaccini G., Betti L., et al. Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis Res Ther.2006;8:R99.
27.
Julien N., Goffaux P., Arsenault P., Marchand S.Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain. 2005;114:295-302.
28.
Wood PB, Patterson JC, 2nd, Sunderland JJ, Tainter KH, Glabus MF, Lilien DLReduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain. 2007;8:51-58.
29.
Wood PB, Schweinhardt P., Jaeger E., et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci. 2007;25:3576-3582.
30.
Guidelines for the Management of Fibromyalgia Syndrome Pain in Adults and Children. American Pain Society Clinical Practice Guideline Series, No.4. 2005. Available at: http://www.ampainsoc.org/pub/fibromyalgia.htm. Accessed January 15, 2008.
31.
Da Silva JA, Danneskiold-Samsøe B., Dincer F., et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536-541.
32.
The Fibromyalgia Impact Questionnaire. Available at: http://www.myalgia.com/FIQ/fiq.pdf. Accessed March 22, 2008.
33.
Goldenberg DL , Felson DT, Dinerman H.A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia . Arthritis Rheum. 1986;29:1371-1377.
34.
Goldenberg DLPharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol. 2007;21:499-511.
35.
Carette S., Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial. Arthritis Rheum. 1994;37:32-40.
36.
Arnold LM, Keck PE Jr, Welge JAAntidrepressant treatment of fibromyalgia. a meta-analysis and review . Psychosomatics. 2000;41:104-113.
37.
Arnold LMDuloxetine and other antidepressants in the treatment of patients with fibromyalgia . Pain Med. 2007;8:S63-S74.
38.
Dick IE, Brochu RM, Purohit Y., Kaczorowski GJ, Martin WJ, Priest BTSodium channel blockade may contribute to the analgesic efficacy of antidepressants . J Pain. 2007;8:315-324.
39.
Arnold LM, Lu Y., Crofford LJ, et al. A double-blind, multi-center trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50: 2974-2984.
40.
Arnold LM, Rosen A., Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5-15.
41.
Patkar AA, Masand PS, Krulewicz S., et al. A randomized, controlled trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007;120:448-454.
42.
Chappell A., Bradley L., Wiltse C.Duloxetine 60-120 mg versus placebo in the treatment of fibromyalgia syndrome . Program and abstracts of the American College of Rheumatology 71st Annual Meeting, Boston, MA . Abstract/ Poster 1543/157 presented November 10, 2007 .
43.
Sayar K., Aksu G., Ak I., Tosun M.Venlafaxine treatment of fibromyalgia. Ann Pharmacother . 2003;37:1561-1565.
44.
Dwight MM, Arnold LM, O'Brien H., Metzger R., Morris-Park E., Keck PE Jr.An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics. 1998;39:14-17.
45.
Zijlstra TR , Barendregt PJ, van de Laar MAF.Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum.2002;46:S105.
46.
Grothe DR, Scheckner B., Albano D.Treatment of pain syndromes with venlafaxine. Pharmacotherapy . 2004;24: 621-629.
47.
Gendreau RM , Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975-1985.
48.
Tofferi JK, Jackson JL, O'Malley PGTreatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum. 2004;51:9-13.
49.
Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JAA comparison of cyclobenzaprine and placebo in the management of fibrositis: a double-blind controlled study. Arthritis Rheum. 1988;31: 1535-1542.
50.
Quimby LG, Gratwick GM, Whitney CD, Block SRA randomized trial of cyclobenzaprine for the treatment of fibromyalgia . J Rheumatol Suppl. 1989;19:140-143.
51.
Reynolds WJ , Moldofsky H., Saskin P., Lue FAThe effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol. 1991;18:452-454.
52.
Tremont-Lukats IW, Megeff C., Backonja MMAnticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs. 2000;60:1029-1052.
53.
Crofford LJ , Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial . Arthritis Rheum. 2005;52:1264-1273.
54.
Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502-514.
Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia. Arthritis Rheum. 2007;56:1336-1344.
57.
Crofford LJ , Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig G.Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM) trial: a 6-month, double-blind, placebo-controlled trial of treatment with pregabalin . J Pain . 2008;136:419-431.
58.
Holman AJ, Myers RRA randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications . Arthritis Rheum. 2005;52: 2495-2505.
59.
Clark S., Tindall E., Bennett RMA double-blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol. 1985 ;12:980-983.
60.
Goldenberg DL, Felson DT, Dinerman H.A randomized controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia . Arthritis Rheum. 1986;29:1371-1377.
61.
Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JKDecreased central mu-opioid receptor availability in fibromyalgia . J Neurosci. 2007;27:10000-10006.
62.
Bennett RM, Kamin M., Karim R., Rosenthal N.Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114: 537-545.
63.
Bennett RM, Schein J., Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NRImpact of fibromyalgia on health related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum . 2005;53: 519-527.
Argoff CEA review of the use of topical analgesics for myofascial pain. Cur Pain Headache Rep. 2002;6: 375-378.
67.
Moldofsky H. , Leu FA, Mously C., Roth-Schechter B., Reynolds WJThe effects of zolpidem in patients with fibromyalgia: a dose ranging, double-blind, placebo-controlled, modified crossover study. J Rheumatol. 1996 ;23:529-533.
68.
Gronblad M. , Nykanen J., Konttinen Y., Jarvinen E., Helve T.Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial . Clin Rheumatol. 1993;12: 186-191.
69.
Drewes AM, Andreasen A., Jennum P., Nielsen KDZopiclone in the treatment of sleep abnormalities in fibromyalgia . Scand J Rheumatol. 1991;20:288-293.
70.
Wood PB, Holman AJ, Jones KDNovel pharmacotherapy for fibromyalgia. Expert Opin Investig Drugs. 2007;16:829-841.
71.
Freedenfeld RN, Murray M., Fuchs PN, Kiser RSDecreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic . Pain Pract. 2006 ;6:112-118.
72.
Nelson KA, Park KM, Robinovitz E., Tsigos C., Max MBHigh-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997 ;48:1212-1218.
73.
Weinbroum AA , Gorodetzky A., Nirkin A., et al. Dextromethorphan for the reduction of immediate and late postoperative pain and morphine consumption in orthopedic oncology patients: a randomized, placebo-controlled, double-blind study. Cancer. 2002;95:1164-1170.
74.
Schaller JL , Behar D.Modafinil in fibromyalgia treatment [letter] . J Neuropsychiatry Clin Neurosci. 2001;13:530-531.
Sarac AJ, Gur A.Complementary and alternative medical therapies in fibromyalgia. Curr Pharm Des. 2006;12:47-57.
77.
Cauffield JS , Forbes HJDietary supplements used in the treatment of depression, anxiety, and sleep disorders. Lippincotts Prim Care Pract. 1999;3:290-304.
78.
Jellin JM, Gregory PJ, Batz F., et al. Alpha hydroxy acids monograph. Pharmacist's Letter/Prescriber's Letter Natural Medicines Comprehensive Database. 7th ed. Stockton, CA: Therapeutics Research Faculty; 2005;33-35.
79.
Massey PBReduction of fibromyalgia symptoms through intravenous nutrient therapy: results of a pilot clinical trial. Altern Ther Health Med . 2007;13(3):32-34.
80.
Rossini M., Di Munno O., Valentini G., et al. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol. 2007;25:182-188.
81.
Teitelbaum JE, Johnson C., St. Cyr J.The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med.2006;12:857-862.
